Cutaneous Lymphoma: Clinical Trials

5 trials for Cutaneous Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 active not recruiting, 1 terminated. 5 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 15Completed 3, Active not recruiting 1, Terminated 1
Phase 21Terminated 1

Follow Cutaneous Lymphoma: new trials by email Literature Review of Cutaneous Lymphoma trials Research Report on Cutaneous Lymphoma

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
ATLCAR.CD30.CCR4 cells, ALTCAR.CD30 cells, Bendamustine - Lymphoma, Immune System Diseases
Phase 1Active not recruitingUNC Lineberger Comprehensive Cancer Center432018-10-292026-06-12
T-VEC in Non-melanoma Skin Cancer
Talimogene Laherparepvec (T-VEC) - Non-melanoma Skin Cancer, Basal Cell Carcinoma
Phase 1CompletedUniversity of Zurich262018-04-192022-03-18
Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma
Istodax, Doxil - Lymphoma, T-Cell Lymphoma
Phase 1CompletedWeiyun Ai242014-03-042020-06-09
Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
Total skin electron beam therapy (TSEBT), Vorinostat - Cutaneous Lymphoma, Cutaneous T-cell Lymphoma
Phase 1 / Phase 2TerminatedStanford University282010-12-012017-11-20
ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells
ATRA plus G-CSF (filgrastim, NEUPOGEN (R)) combination - Multiple Myeloma, Cutaneous Lymphoma
Phase 1CompletedPeter MacCallum Cancer Centre, Australia62005-03-012006-11-17

Narrower conditions

Lymphoma, T-Cell, Cutaneous (5)  ·  Lymphoma (2)  ·  Carcinoma, Basal Cell (1)  ·  Carcinoma, Merkel Cell (1)  ·  Carcinoma, Squamous Cell (1)  ·  Immune System Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Lymphatic Diseases (1)  ·  Lymphoma, T-Cell (1)  ·  Lymphomatoid Papulosis (1)  ·  Lymphoproliferative Disorders (1)  ·  Multiple Myeloma (1)  ·  Mycosis Fungoides (1)  ·  Neoplasms (1)  ·  Sezary Syndrome (1)

Broader conditions

Hemic and Lymphatic Diseases (5)  ·  Lymphoma, Non-Hodgkin (5)  ·  Neoplasms by Histologic Type (5)  ·  Immune System Diseases (4)  ·  Immunoproliferative Disorders (4)  ·  Lymphatic Diseases (4)  ·  Lymphoma, T-Cell (4)  ·  Lymphoproliferative Disorders (4)  ·  Neoplasms (4)  ·  Lymphoma (3)  ·  Adenocarcinoma (1)  ·  Blood Protein Disorders (1)  ·  Carcinoma (1)  ·  Carcinoma, Neuroendocrine (1)  ·  Cardiovascular Diseases (1)

Interventions

Bendamustine Hydrochloride (1)  ·  Filgrastim (1)  ·  Granulocyte Colony-Stimulating Factor (1)  ·  Tretinoin (1)  ·  Vorinostat (1)  ·  fludarabine (1)  ·  liposomal doxorubicin (1)  ·  romidepsin (1)  ·  talimogene laherparepvec (1)

Sponsors

Peter MacCallum Cancer Centre, Australia (1)  ·  Stanford University (1)  ·  UNC Lineberger Comprehensive Cancer Center (1)  ·  University of Zurich (1)  ·  Weiyun Ai (1)

Countries

United States (3)  ·  Australia (1)  ·  Switzerland (1)

Top investigators

Ai Wei, M.D. (1)  ·  Kirsten E Herbert, MBBS (1)  ·  Miles Prince, MBBS (1)  ·  Natalie Grover, MD (1)  ·  Reinhard Dummer, Prof. Dr. (1)  ·  Youn H Kim (1)

NIH funding

R01CA247497 (1)